Login to Your Account



No Remicade Valuation Spoils Peptech, Agenix A$500 Merger

By Mark Lawson


Wednesday, June 23, 2004
SYDNEY, Australia - A friendly A$500 million (US$345 million) merger that promised to create Australia's largest pure biotech company has been called off after hitting a major obstacle over one partner's dispute with a U.S. company. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription